文献速递复苏、休克与脓毒症心脑血管急症

双序贯除颤治疗难治性心室颤动心脏骤停:系统评价

Double (dual) sequential defibrillation for refractory ventricular fibrillation cardiac arrest: A systematic review.
PubMed 文献 · Resuscitation · 2020-06-16
一句话结论系统评价显示双序贯除颤与标准除颤策略在神经预后、出院存活、入院存活、自主循环恢复及室颤/无脉性室速终止方面无差异,现有证据存在严重偏倚风险,需高质量研究进一步回答。

该系统评价按PRISMA进行并在PROSPERO注册(ID: CRD42020152575),检索Embase、PubMed和Cochrane图书馆至2020年2月28日,纳入成人室颤/无脉性室速患者,排除病例研究、少于5例的病例系列、会议摘要、模拟研究和临床试验方案。最终纳入9项研究(队列研究4项、病例系列3项、病例对照研究1项、前瞻性先导临床试验1项),所有研究偏倚风险为严重或极高,未进行Meta分析。总体未发现双序贯除颤与标准除颤策略在神经预后、出院存活、入院存活、自主循环恢复或室颤/无脉性室速终止方面存在差异。结论认为双序贯除颤与院外心脏骤停结局改善无关,但现有文献在解释上存在诸多局限,需要进一步高质量证据回答这一重要问题。

要点

  • 系统评价纳入9项研究(队列研究4项、病例系列3项、病例对照研究1项、前瞻性先导临床试验1项),所有研究偏倚风险为严重或极高,未进行Meta分析。
  • 双序贯除颤与标准除颤策略在神经预后、出院存活、入院存活、自主循环恢复及室颤/无脉性室速终止方面均未发现差异。
  • 纳入研究为成人室颤/无脉性室速患者,排除病例研究、少于5例的病例系列、会议摘要、模拟研究和临床试验方案。
  • 结论指出双序贯除颤与院外心脏骤停结局改善无关,但现有文献在解释上存在诸多局限,需要进一步高质量证据。

适用人群与场景

  • 成人室颤/无脉性室速(VF/pVT)患者,任何场景。
  • 排除病例研究、少于5例的病例系列、会议摘要、模拟研究和临床试验方案。

研究设计与关键结果

  • 系统评价按PRISMA进行并在PROSPERO注册(ID: CRD42020152575),检索Embase、PubMed和Cochrane图书馆自建库至2020年2月28日。
  • 初检识别314项研究,标题和摘要阶段筛选130项,全文筛选10项,最终纳入9项分析。
  • 纳入研究类型:队列研究4项、病例系列3项、病例对照研究1项、前瞻性先导临床试验1项。
  • 所有研究偏倚风险为严重或极高(使用ROBINS-I或ROB-2评估),未进行Meta分析。
  • 总体未发现双序贯除颤与标准除颤策略在神经预后、出院存活、入院存活、自主循环恢复或室颤/无脉性室速终止方面存在差异。

证据类型、等级与局限

  • 证据类型:系统评价,纳入队列研究4项、病例系列3项、病例对照研究1项、前瞻性先导临床试验1项。
  • 所有研究偏倚风险为严重或极高,未进行Meta分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该系统评价未发现双序贯除颤与标准除颤策略在神经预后、出院存活、入院存活、自主循环恢复或室颤/无脉性室速终止方面存在差异。
  • 原文结论指出双序贯除颤与院外心脏骤停结局改善无关,但现有文献在解释上存在诸多局限,需要进一步高质量证据回答这一重要问题。

指南或共识出处

  • Resuscitation

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Cardiac arrests associated with shockable rhythms such as ventricular fibrillation or pulseless VT (VF/pVT) are associated with improved outcomes from cardiac arrest. The more defibrillation attempts required to terminate VF/pVT, the lower the survival. Double sequential defibrillation (DSD) has been used for refractory VF/pVT cardiac arrest despite limited evidence examining this practice. We performed a systematic review to summarize the evidence related to the use of DSD during cardiac arrest.

METHODS: This review was performed according to PRISMA and registered on PROSPERO (ID: CRD42020152575). We searched Embase, Pubmed, and the Cochrane library from inception to 28 February 2020. We included adult patients with VF/pVT in any setting. We excluded case studies, case series with less than five patients, conference abstracts, simulation studies, and protocols for clinical trials. We predefined our outcomes of interest as neurological outcome, survival to hospital discharge, survival to hospital admission, return of spontaneous circulation (ROSC), and termination of VF/pVT. Risk of bias was examined using ROBINS-I or ROB-2 and certainty of studies were reported according to GRADE methodology.

RESULTS: Overall, 314 studies were identified during the initial search. One hundred and thirty studies were screened during title and abstract stage and 10 studies underwent full manuscript screening, nine included in the final analysis. Included studies were cohort studies (n = 4), case series (n = 3), case-control study (n = 1) and a prospective pilot clinical trial (n-1). All studies were considered to have serious or critical risk of bias and no meta-analysis was performed. Overall, we did not find any differences in terms of neurological outcome, survival to hospital discharge, survival to hospital admission, ROSC, or termination of VF/pVT between DSD and a standard defibrillation strategy.

CONCLUSION: The use of double sequential defibrillation was not associated with improved outcomes from out-of-hospital cardiac arrest, however the current literature has a number of limitations to interpretation. Further high-quality evidence is needed to answer this important question.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Deakin CD, Morley P, Soar J, et al. Double (dual) sequential defibrillation for refractory ventricular fibrillation cardiac arrest: A systematic review. Resuscitation. 2020. PMID: 32561473. doi:10.1016/j.resuscitation.2020.06.008

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。